Announcement • 7h
Atlas Metals Group plc, Annual General Meeting, Jun 03, 2026 Atlas Metals Group plc, Annual General Meeting, Jun 03, 2026. Location: the offices of orrick, herrington and sutcliffe uk llp, 107 cheapside, ec2v 6dn, london United Kingdom New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.0m). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (165% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£2.61m market cap, or US$3.52m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Announcement • Mar 05
Atlas Metals Group plc announced that it expects to receive £2.375 million in funding from Yorkville Advisors Global LP Atlas Metals Group plc announced a private placement and entered into an agreement with A II PN Ltd, an institutional investor managed by Yorkville Advisors Global, LP for a convertible loan of £2,500,000 on March 5, 2026. The Funding Facility is made up of two convertible loans, a first loan of £500,000 and a second loan of up to £2,000,000. The First Loan is expected to be provided to the Company following satisfaction of certain customary conditions precedent and will be advanced net of fees and a 5% original issue discount on satisfaction of those conditions for payment. The Lender may, at any time for so long as any amount is outstanding under the Funding Facility, elect to convert amounts outstanding under the Loans into new ordinary shares in the Company at a conversion price equal to 120% of the closing price of the Ordinary Shares on the trading day immediately prior to the Completion Date. Conversion is subject to certain customary scaling-back provisions, which prevent the Lender from holding more than 29.99% of the Company upon conversion. The First Loan has a maturity of 104 days from the Completion Date and will be repaid by way of monthly amortization over that period, unless the Lender has exercised its conversion rights under the Funding Facility. The First Loan carries interest at 5% per annum, accruing from the Completion Date and calculated on a daily basis. The Second Loan of up to £2,000,000 will be available for drawdown subject to the satisfaction of certain conditions. These conditions include the Company having made two consecutive monthly repayments in respect of the First Loan, a minimum median average daily trading value of £50,000 over the preceding 60 trading days, and the closing price of the Ordinary Shares being above the Conversion Price. The Second Loan will be subject to deductions comprising a 5% original issue discount, a 1% commitment fee, and an amount to repay any outstanding balance of the First Loan. Repayment of the Second Loan will be by way of monthly amortization over a period of approximately 11 months, commencing 60 days after drawdown, unless the Lender has previously exercised its conversion rights. The Second Loan carries interest at 5% per annum accruing from the date that the Second Loan is drawn down by the Company and calculated on a daily basis. Pursuant to the Funding Facility, the Company has entered into the Warrant Agreement with the Lender, pursuant to which the Company will issue to the Lender warrants equal to 25% of each monthly amortization payment amount ("Warrants"), with an exercise price equal to 115% of the closing price of the Ordinary Shares on the date that the First Loan is provided to the Company. The Warrants will expire three years after issue. The Company may require the Warrants to be exercised if the Ordinary Shares trade at least 30% above the warrant exercise price for 20 consecutive trading days. The aggregate subscription price payable on exercise of the Warrants may be set off by the Lender against the outstanding balance of the Loans. 
